LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Dr Reddy's Laboratories Ltd-ADR

Chiusa

SettoreSettore sanitario

15.05 -1.76

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

14.96

Massimo

15.32

Metriche Chiave

By Trading Economics

Entrata

1.8B

16B

Vendite

1.5B

85B

P/E

Media del settore

19.628

50.291

EPS

19.11

Rendimento da dividendi

0.62

Margine di Profitto

18.66

Dipendenti

27,811

EBITDA

985M

25B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+10.24% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.62%

2.40%

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

10B

13B

Apertura precedente

16.81

Chiusura precedente

15.05

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

9 mag 2025, 18:56 UTC

Utili

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 mag 2025, 18:56 UTC

Utili

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

23 gen 2025, 17:46 UTC

Utili

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 gen 2025, 17:42 UTC

Utili

Dr. Reddy's 3Q Rev INR83.59B

5 nov 2024, 11:01 UTC

Utili

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov 2024, 11:00 UTC

Utili

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov 2024, 10:57 UTC

Utili

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov 2024, 10:57 UTC

Utili

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Confronto tra pari

Modifica del prezzo

Dr Reddy's Laboratories Ltd-ADR Previsione

Obiettivo di Prezzo

By TipRanks

10.24% in crescita

Previsioni per 12 mesi

Media 16.9 USD  10.24%

Alto 16.9 USD

Basso 16.9 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Dr Reddy's Laboratories Ltd-ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 13.84Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Weak Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.